文献速递心力衰竭与心肌病

氯苯唑酸治疗转甲状腺素蛋白淀粉样心肌病的成本效益分析

Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
PubMed 文献 · Circulation · 2020-02-12

本研究基于ATTR-ACT试验等数据构建马尔可夫模型,评估氯苯唑酸对比常规治疗用于转甲状腺素蛋白淀粉样心肌病患者的成本效益。结果显示,氯苯唑酸每增加1个质量调整生命年需多花费约88万美元,在当前美国定价下不具备成本效益,需大幅降价才可能达到10万美元/QALY的阈值。

要点

  • 以10万美元/QALY为阈值,氯苯唑酸在全部概率模拟中均不具成本效益。

核心结论

  • 氯苯唑酸可带来显著临床获益,但在当前美国定价下远超常规成本效益阈值。

研究设计与样本

  • 基于ATTR-ACT试验、文献、FDA审评文件、医疗索赔和全国调查数据构建马尔可夫模型,模拟野生型或变异型转甲状腺素蛋白淀粉样心肌病伴心衰患者(平均年龄74.5岁)。
  • 比较无疾病特异性治疗(常规治疗)与氯苯唑酸治疗,从美国医疗保健部门视角评估终身增量成本效益比和年度预算影响。

关键数值与推荐

  • 以10万美元/QALY为阈值,氯苯唑酸具有成本效益的概率为0%。

临床怎么用

  • 在当前美国定价下,氯苯唑酸的临床获益虽显著但成本效益极低,可能限制其可及性和 uptake。
  • 需大幅降低药物成本才可能使氯苯唑酸在常规成本效益阈值下被接受。

局限性

  • 结果对氯苯唑酸长期疗效的假设敏感。
  • 模型基于ATTR-ACT试验的30个月数据外推,长期疗效存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces all-cause mortality and cardiovascular hospitalizations and slows decline in quality of life compared with placebo. In May 2019, tafamidis received expedited approval from the US Food and Drug Administration as a breakthrough drug for a rare disease. However, at $225 000 per year, it is the most expensive cardiovascular drug ever launched in the United States, and its long-term cost-effectiveness and budget impact are uncertain. We therefore aimed to estimate the cost-effectiveness of tafamidis and its potential effect on US health care spending. METHODS: We developed a Markov model of patients with wild-type or variant transthyretin amyloid cardiomyopathy and heart failure (mean age, 74.5 years) using inputs from the ATTR-ACT trial (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial), published literature, US Food and Drug Administration review documents, healthcare claims, and national survey data. We compared no disease-specific treatment ("usual care") with tafamidis therapy. The model reproduced 30-month survival, quality of life, and cardiovascular hospitalization rates observed in ATTR-ACT; future projections used a parametric survival model in the control arm, with constant hazards reduction in the tafamidis arm. We discounted future costs and quality-adjusted life-years by 3% annually and examined key parameter uncertainty using deterministic and probabilistic sensitivity analyses. The main outcomes were lifetime incremental cost-effectiveness ratio and annual budget impact, assessed from the US healthcare sector perspective. This study was independent of the ATTR-ACT trial sponsor. RESULTS: Compared with usual care, tafamidis was projected to add 1.29 (95% uncertainty interval, 0.47-1.75) quality-adjusted life-years at an incremental cost of $1 135 000 (872 000-1 377 000), resulting in an incremental cost-effectiveness ratio of $880 000 (697 000-1 564 000) per quality-adjusted life-year gained. Assuming a threshold of $100 000 per quality-adjusted life-year gained and current drug price, tafamidis was cost-effective in 0% of 10 000 probabilistic simulations. A 92.6% price reduction from $225 000 to $16 563 would be necessary to make tafamidis cost-effective at $100 000/quality-adjusted life-year. Results were sensitive to assumptions related to long-term effectiveness of tafamidis. Treating all eligible patients with transthyretin amyloid cardiomyopathy in the United States with tafamidis (n=120 000) was estimated to increase annual healthcare spending by $32.3 billion. CONCLUSIONS: Treatment with tafamidis is projected to produce substantial clinical benefit but would greatly exceed conventional cost-effectiveness thresholds at the current US list price. On the basis of recent US experience with high-cost cardiovascular medications, access to and uptake of this effective therapy may be limited unless there is a large reduction in drug costs.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kazi DS, Bellows BK, Baron SJ, et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020. PMID: 32078382. doi:10.1161/CIRCULATIONAHA.119.045093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。